Eurotek Competitors

Omnicare, a CVS Health company, based in Cincinnati, Ohio, provides comprehensive pharmaceutical services to patients and providers across the United States. As the market-leader in professional pharmacy, related consulting and data management services for skilled nursing, assisted living and other chronic care institutions, Omnicare leverages its unparalleled clinical insight into the geriatric market along with some of the industry's most innovative technological capabilities to the benefit of its long-term care customers. Omnicare also provides key commercialization services for the bio-pharmaceutical industry through its Specialty Care Group.

Cambridge Healthtech Institute – Your Life Science Network Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech, and academic organizations. CHI’s portfolio of products includes Cambridge Healthtech Institute Conferences, Barnett Educational Services, Cambridge Meeting Planners and Healthtech Publishing, which includes publications such as Bio-IT World, Clinical Informatics News, and Diagnostics World, as well as numerous e-newsletters. Founded in 1992, Cambridge Healthtech Institute strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments. Basic research related to commercial implications is covered, with a heavy emphasis placed on end-user insights into new products and technology as well as coverage on the strategy behind the business. The executive team has a combined 170+ years of experience and drives the CHI portfolio to deliver cutting-edge information and the most up-to-date research.

Cygnus Technologies, part of Maravai LifeSciences, provides best-in-class analytical tools and solutions to help companies developing therapeutic proteins, vaccines, antibodies, plasma derivatives and gene therapies to ensure the safety of biotherapeutics prior to human trials, regulatory approval and commercial release. As the biopharmaceutical industry’s partner in analytics for host cell proteins (HCP), other process-related impurities, and viral clearance, Cygnus’ off-the-shelf products and custom services ultimately improve bioprocess development for faster regulatory approval and better clinical outcomes. Founded by Ken Hoffman in 1997, Cygnus is an industry pioneer responsible for developing and commercializing the first generic assay kits for HCP detection. Its reputation for quality is recognized by the industry and global regulatory agencies; as of April 1, 2026, Cygnus’ off-the shelf and custom assays have been used for lot release testing of multiple licensed novel biologics, biosimilars, vaccines and 28 FDA- and EMA-approved cell and gene therapies. Cygnus continues to advance the science of bioprocess impurity detection with new breakthroughs, including its Antibody Affinity Extraction™ (AAE) technology and orthogonal methods of HCP analysis that integrate Mass Spectrometry, AAE and ELISA. To reduce the cost and risk associated with viral clearance studies, Cygnus offers an innovative approach that utilizes non-infectious mock virus particles through its MockV™ virus clearance kits. Cygnus’ proprietary technologies, available through its products and custom assays/services, set the gold standard for enabling HCP and other bioprocess impurity antibody assays. Cygnus delivers best-in-class customer service and technical expertise, operational excellence and ISO-9001:2015 certified quality management systems. Located in Leland, North Carolina, Cygnus Technologies is online at www.cygnustechnologies.com.